1. Home
  2. UIS vs SGMT Comparison

UIS vs SGMT Comparison

Compare UIS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$2.86

Market Cap

205.4M

Sector

Technology

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.04

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UIS
SGMT
Founded
1942
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
205.4M
204.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
UIS
SGMT
Price
$2.86
$6.04
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$5.88
$29.71
AVG Volume (30 Days)
655.7K
498.6K
Earning Date
02-17-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,921,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$1.73
52 Week High
$7.54
$11.41

Technical Indicators

Market Signals
Indicator
UIS
SGMT
Relative Strength Index (RSI) 42.75 45.24
Support Level $2.88 $5.95
Resistance Level $3.12 $6.60
Average True Range (ATR) 0.16 0.31
MACD -0.03 0.05
Stochastic Oscillator 9.92 49.17

Price Performance

Historical Comparison
UIS
SGMT

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: